Login to Your Account

Clinic Roundup

Wednesday, July 17, 2013

• Oncogenex Pharmaceuticals Inc., of Bothell, Wash., said enrollment was completed in Borealis-1, a company-sponsored Phase II trial testing heat-shock protein 27 inhibitor OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer. About 180 patients were recruited into the study.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription